Taurine in Septic Critically Ill Patients: Plasma versus Blood

Ata Mahmoodpoor1, Afshane Farjami1,3, Niloufar Farzan4, Hamed Hamishehkar2, Parina Asgharian2, Sarvin Sanaie6, Kamran Shadvar1, Farnaz Naeimzadeh2, Hadi Hamishehkar*2

1Department of Anesthesiology, Tabriz University of Medical Sciences, Tabriz, Iran.
2Food and Drug Safety Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
4Iranian Evidence Based Medicine Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.
5Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
6Neurosciences Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
7Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
8Clinical Research Development Unit of Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Article info
Article History:
Received: March 31, 2021
Revised: August 1, 2021
Accepted: September 28, 2021
epublished: October 9, 2021

Keywords:
Critically ill, Sepsis, Taurine

Abstract
Purpose: Sepsis and systemic inflammatory response syndrome (SIRS) encompass various problems throughout the body, and two of its major problems are the creation of oxidative substances in the body and decrease of the body's antioxidant capacity to deal with the stress and organ damage. Optimal enteral nutrition fortified with antioxidant or immunomodulator amino acid is a hot topic concerning sepsis in the critical care setting. Taurine plays a protective role as an antioxidant in cells that is likely to have a protective role in inflammation and cytotoxicity.

Methods: In the present study, 20 septic patients and 20 healthy volunteers were enrolled. The blood and plasma taurine levels of the patients on days 1, 3 and 7 were measured. Blood and plasma taurine level and the correlation between them, organ failure, and severity of the disease were assessed.

Results: Taurine concentrations in the plasma of the septic patients were significantly lower than control group, and the whole blood concentrations were significantly higher than those of the control group (P<0.001). There was not a significant correlation between the blood and plasma taurine levels in control and septic patients. In addition, there was not any correlation between the severity of the disease, organ failure, mortality, and plasma as well as the blood concentration of taurine.

Conclusion: In septic patients, taurine concentration in plasma and blood are low and high, respectively. These concentrations are not linked to each other and not associated with the patients' outcome, and the disease severity, and organ failure.

Introduction
Oxidative injuries and inflammation are two main issues in sepsis. In addition to prescribing antibiotics for the treatment of sepsis, the use of supplements to control the mortality of sepsis has been considered and studied as well. Taurine as an imperative supplement, is a sulfonated amino acid derived from methionine and cysteine metabolism, and it has been suggested to have different functions such as membrane stabilization, osmoregulation, bile salt formation, and modulation of intracellular calcium homeostasis and is present in lymphocytes have abandon reserve of taurine which may cause changes in taurine concentration. Taurine therapy may also have potential advantages in reducing the destruction of neutrophils and tissue damage due to sepsis, which is unrelated to antioxidant effects.

Taurine is not incorporated into proteins, which may dissociate taurine levels from changes in protein synthetic and catabolic rates, and from the consequent changes in the plasma amino acid pool. Changes in osmotic imbalance, cell proliferation, and hepatic encephalopathy may cause changes in taurine concentration.

Previous studies have reported conflicting and contradictory results from changes in the concentration of taurine in blood and plasma in sepsis. However, taurine was suggested to be a utile and effective supplement, which may be indicated in sepsis treatment. The primary goal of this research was to evaluate the change and correlation in the plasma and whole blood concentration of taurine over time in severe septic patients.
and as the second goal, to study the relation between taurine concentration, clinical data, and outcome.

Methods

Patients and study protocol

In the present prospective case-control study, 20 consecutive critically septic patients over 18 years within 24 hours after intensive care unit (ICU) admission and under mechanical ventilation were included. Sepsis is a syndrome caused by a disruption of the host’s immune response to infection including abnormal physiological and biological abnormalities. All of the included patients were admitted to the 12-bed close format general ICU of a university-affiliated hospital from April 2015 to July 2016. The blood samples were taken from 20 healthy volunteers as the control group.

The criteria for enrollment in the septic group was the presence of at least one positive culture (blood, urine, tracheal aspirates, wound, and CSF fluid) in addition to having systemic inflammatory response syndrome (SIRS) symptoms. The negative culture even with a high probability of sepsis was excluded from the study. Patient enrollment was based on the presence of at least two of the following SIRS criteria: body temperature (> 38°C or < 36°C), tachycardia > 90 beats/min, respiratory rate > 20 breaths/min or Paco2 < 32 torr, white blood cell count > 12,000 cells/µL or < 4,000 cells/µL, or > 10% immature (band) forms. Exclusion criteria were pregnancy, hematologic malignancy, agranulocytosis, intolerance to enteral nutrition, and cirrhosis. In the early hospitalization, demographic characteristics (weight, age, sex, body mass index) were recorded for all the patients, and central venous lines and Foley catheters were established, and all the patients were monitored for ECG and pulse oximetry. The illness severity and organ dysfunction were calculated by the Acute Physiology and Chronic Health (APACHE II) score and Sequential Organ Failure Assessment (SOFA) score, respectively. All the patients were feed via a Nasogastric tube. Pre-formulated standard enteral nutrition (Ensure®, Abbot, United States) was started at 20 ml/h, and the dose was increased by 20 ml/h if the gastric retention volume remained < 150 ml/h. In the case of intolerance, intravenous (IV) metoclopramide was initiated. Patients with a lack of tolerance to enteral nutrition for more than 24 hours were excluded from the study.

Total energy expenditure was calculated using the Harris–Benedict equation. No vitamins, supplements and trace elements were added to the patients’ daily nutrition support.

To measure taurine concentrations in blood and plasma, 5 mL of blood from the patients was taken on days 1 (during 24 hours), 3, and 7 after diagnosis of sepsis. Samples were divided into two parts, one part as whole blood restored and another part was centrifuged (PIT 320, Pole Ideal Tajhiz Co®) and plasma was separated. All the samples were frozen at -70°C (NF305 AEG, Himalia®).

Taurine assay method

Kamp and colleagues modified the method by HPLC with a fluorescence detector was used to measure taurine levels. To calibrate the standard curve, 10 mL solution of taurine (10 mg) in 50% methanol was prepared. Five different taurine concentrations (10, 20, 40, 60, 80 and 100 µg/mL in water) were prepared and used as calibrators. When the samples were defrosted, then 100 µL the standard solution and 100 µL plasma were mixed for 30 seconds on the vortex (LS-100, Labtron®) then remained about 20 minutes at the lab temperature. Subsequently, it was diluted (1:10 v/v) in methanol then centrifuged for 5 minutes at a speed of 12,000 rpm and the supernatant was separated. Finally, 250 µL methanol solution with 200 µL of borate buffer (618 mg boric acid in 100 mL water, pH = 10 with NaOH), 250 µL methanol, 250 µL o-phthalaldehyde (OPA) (20 mg/mL in methanol) and 50 µL 3-mercapto-propionic acid (MPA) (in fume hood) were prepared and then kept in dark for 2 minutes. Correspondingly, prepared samples were subjected to HPLC apparatus (column: KNAUER C18 4 µm 15 cm, mobile phase: 85% disodium hydrogen phosphate 0.0125M and 15%).

To calibrate blood samples, 100 µL blood, 100 µL solution with standard concentrations and 800 acetone were mixed and centrifuged for 5 minutes at 12,000 rpm. Then, 125 µL over solution, 125 µL methanol, 120 µL, 50 µL OPA borate buffer and 25 µL MPA were mixed for 30 seconds on the vortex and after two minutes, 20 µL was injected. This method was used for all concentrations.

Statistical analysis

The results of the study conducted by Chiarla et al were used for sample size estimation. Assuming α = 0.05 and power = 0.9, the sample size of less than 10 was calculated using the software Power & Sample Size (PS), Version 3/0. Supposing 30% changes in laboratory parameters, to increase the study reliability, 20 septic patients and 20 healthy subjects were enrolled. We verified the existence of normality in the quantitative variables using the Kolmogorov–Smirnov test. Independent t test and analysis of variance (ANOVA), as well as chi-square test were used to compare quantitative and qualitative variables, respectively. The Pearson and Spearman correlations were used to evaluate the correlation between parametric and nonparametric data. Repeated measures analysis of variance was used to detect significant changes in the blood and plasma taurine concentration for patients during sequential measured times and also between dead and alive patients. A P value of less than 0.05 was considered statistically significant.

Result and Discussion

In this study, 41 patients were enrolled. Table 1 presents...
Taurine in septic critically ill patients

Advanced Pharmaceutical Bulletin, 2023, Volume 13, Issue 1

Demographic data. Owing to death and transference to other wards, the number of patients on the third and seventh days dropped to 17 and 10 cases, respectively.

Taurine concentrations in plasma in the control group were significantly higher than plasma concentrations measured in the patients at all times, but blood levels of taurine in the control group are significantly lower than those in the patients. In the patients' taurine levels in blood and plasma on days 1, 3, 7, were not significantly different. $P<0.05$ was compared with the measured taurine levels in the patients.

There was no correlation between sex, APACHE II score, SOFA score, vasopressor use and PaO2/FiO2 (as a respiratory index) with plasma and blood concentration of taurine. There was an opposite non-significant correlation between age and taurine plasma as well as blood concentration.

There was no correlation between mean arterial pressure and blood and plasma concentrations in septic patients with taurine, but the correlation between taurine concentrations in plasma on days 3 and 7 and lactate and taurine concentrations in blood on day 7 in septic patients was statistically significant.

Sepsis causes progressive damage in various organs. Septic shock progress with a significant reduction in blood pressure may lead to death. Although overall mortality of sepsis has declined over the last decade, it continues to be a disease associated with high mortality. It seems that antibiotics therapy is not an effective treatment to increase the chance of survival in septic patients. Taurine deficiency in the plasma of septic patients makes taurine as a complementary effective treatment.

Taurine is a free amino acid including two special features compared to other amino acids: i) No participation into proteins and peptides. ii) Unique intracellular transport system.

Table 1. Demographic, microbiological, and baseline data at the start of study

| Characteristics | Mean ± SD | P value |
|-----------------|----------|---------|
| **Age**         |          | 0.054   |
| Patients        | 60.7 ± 19.4 |         |
| Controls        | 50.9 ± 9.7  |         |
| **Gender (male/female)** |  |        |
| Patients        | 10:10     | 0.65    |
| Controls        | 11:9      |         |
| **Weight**      |          |         |
| Patients        | 78.6 ± 11.7 | 0.06   |
| Controls        | 85.6 ± 11.4 |         |
| **BMI**         |          |         |
| Patients        | 25.2 ± 2.7 | 0.16    |
| Controls        | 26.3 ± 2.5 |         |
| **The reason for hospitalization** |   |         |
| Trauma          | 6        |         |
| Pulmonary Emboli| 4        |         |
| Cerebrovascular disease | 4    |         |
| Sepsis          | 3        |         |
| Post CPR        | 3        |         |
| **Type of microbiology in septic patients** |   |         |
| Gram +          |          |         |
| Staphylococcus aureus | 4         |         |
| Staphylococcus epidermidis | 1      |         |
| Gram -          |          |         |
| Escherichia coli | 3        |         |
| Pseudomonas aeruginosa | 2     |         |
| Acinetobacter baumannii | 5     |         |
| Klebsiella pneumonia | 3     |         |
| Fungi           |          |         |
| Candida albicans | 2        |         |
| APACHE II (admission) | 20.7 ± 7.2 |   |
| SOFA (admission) | 9.3 ± 2.5  |         |

Data is presented as mean ± SD or number.

APACHE II, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; CPR, cardiopulmonary resuscitation; SOFA, Sequential Organ Failure Assessment.

Figure 1. Taurine concentrations in plasma versus blood in the control group and the patients. This figure shows that taurine concentrations in plasma in the control group are significantly higher than those in the patients, but blood levels of taurine in the control group are significantly lower than those in the patients. In the patients’ taurine levels in blood and plasma on days 1, 3, 7, were not significantly different. $P<0.05$ was compared with the measured taurine levels in the patients.

Figure 2, Table 2. Table 3 and Figure 3 present the plasma and blood concentration of taurine in dead and alive septic patients. There is no significant correlation between blood and plasma concentrations in dead and alive patients. Furthermore, repeated measurements analysis for plasma and blood taurine levels during the study days between dead and alive patients showed no significant change ($P=0.61$ and $P=0.79$) (Figure 3, Table 3)

There was no correlation between mean arterial pressure and blood and plasma concentrations in septic patients with taurine, but the correlation between taurine concentrations in plasma on days 3 and 7 and lactate and taurine concentrations in blood on day 7 in septic patients was statistically significant (Table 5).

Sepsis causes progressive damage in various organs. Septic shock progress with a significant reduction in blood pressure may lead to death. Although overall mortality of sepsis has declined over the last decade, it continues to be a disease associated with high mortality. It seems that antibiotics therapy is not an effective treatment to increase the chance of survival in septic patients. Taurine deficiency in the plasma of septic patients makes taurine as a complementary effective treatment.
Therefore, it is necessary to consider both intracellular and extracellular concentrations. Additional taurine in a normal diet excretes in the urine. In the case of limited access to taurine, kidneys increase reabsorption and decrease the excretion of taurine, leading to stable taurine level in the body.

The present study results indicated that the taurine concentration in the plasma of septic patients during 1, 3 and 7 days after entering the study was significantly lower than that of the control group. Furthermore, the blood taurine concentration was higher than that of the control group in all of samplings days.

Paauw et al studied nine traumatic critical patients and showed that taurine concentration in the plasma of the patients was significantly reduced to 60% of that of the control group. This result demonstrated the necessity of taurine administration after injury.

Engel et al tested 32 septic and traumatic patients and reported that taurine concentration in the plasma trauma was significantly reduced after trauma, supporting our

![Figure 2](image1.png)

**Figure 2.** Correlation between taurine concentrations in plasma and blood in the control group and the patients on days 1, 3, 7. This figure shows that there is no significant correlation between the blood and plasma concentrations in the control group and the patients.

![Figure 3](image2.png)

**Figure 3.** Taurine concentrations in plasma and blood in alive septic patients versus dead septic patients. This figure shows that there is no significant correlation between blood and plasma concentrations of the dead and alive patients.

| Taurine concentration | N   | Mean ± SD (µg/mL) | P value* |
|-----------------------|-----|-------------------|----------|
| Plasma 1              | 20  | 7.76 ± 3.15       | 0.002    |
| Plasma 3              | 16  | 8.62 ± 4.97       | 0.04     |
| Plasma 7              | 10  | 8.16 ± 3.04       | 0.03     |
| Blood 1               | 20  | 62.00 ± 19.73     | 0.000    |
| Blood 3               | 17  | 59.41 ± 19.31     | 0.000    |
| Blood 7               | 10  | 63.43 ± 17.93     | 0.000    |
| Plasma                | 20  | 11.43 ± 3.95      |          |
| Blood                 | 20  | 34.20 ± 8.54      |          |

* Results based on t test comparing mean plasma and blood taurine concentration of patients with plasma and blood taurine concentration in control group.

| Taurine Concentration (µg/ml) |
|------------------------------|
| Alive Septic Patients        |
| Dead Septic Patients         |

Table 2. The taurine concentration in blood and plasma in patients and controls.
Table 3. Taurine concentrations in blood and plasma in survived and died septic patients

|          | Plasma 1  | Plasma 3  | Plasma 7  | Blood 1     | Blood 3     | Blood 7    |
|----------|-----------|-----------|-----------|-------------|-------------|------------|
| Alive    | 8.24 ± 3.44 | 9.44 ± 5.63 | 7.88 ± 3.10 | 63.53 ± 18.93 | 62.07 ± 21.84 | 60.53 ± 17.26 |
| Dead     | 6.63 ± 2.21  | 6.81 ± 2.75  | 8.84 ± 3.45  | 58.43 ± 22.94  | 53.02 ± 10.39  | 70.21 ± 21.32  |

Table 4. Correlation of age and the blood and plasma taurine concentrations in septic patients and control

| Age   | Plasma 1 | Plasma 3 | Plasma 7 | Blood 1 | Blood 3 | Blood 7 |
|-------|----------|----------|----------|---------|---------|---------|
| Patients | -0.066  | -0.012  | -0.042  | -0.231  | -0.363  | -0.382  |
| Sig. (2-tailed) | 0.782  | 0.966  | 0.907  | 0.127  | 0.152  | 0.276  |
| N     | 20       | 17       | 10       | 20      | 17      | 10      |
| Control | 0.196  | 0.205  | 0.075  | 0.372  |
| N     | 20       |          |          |         |         |         |

Table 5. Correlation of age and the blood and plasma taurine concentrations in septic patients

| Lactate 1 | Correlation | Plasma 1 | Blood 1 | Plasma 3 | Blood 3 | Plasma 7 | Blood 7 |
|-----------|-------------|----------|---------|----------|---------|----------|---------|
| Sig. (2-tailed) | 0.001 | 0.200  |          |          |         |          |         |
| Lactate 3 | Correlation | -0.741  | 0.115  |          |         |          |         |
| Sig. (2-tailed) | 0.001 | 0.661  |          |         |         |          |         |
| Lactate 7 | Correlation | 0.027  | -0.077 |          |         |          |         |
| Sig. (2-tailed) | 0.909 | 0.48   |          |         |         |          |         |
| SOFA 1   | Correlation | -0.289  | -0.075 |          |         |          |         |
| Sig. (2-tailed) | 0.277 | 0.774  |          |         |         |          |         |
| SOFA 3   | Correlation | 0.027  | -0.077 |          |         |          |         |
| Sig. (2-tailed) | 0.909 | 0.48   |          |         |         |          |         |
| SOFA 7   | Correlation | -0.217  | -0.292 |          |         |          |         |
| Sig. (2-tailed) | 0.546 | 0.413  |          |         |         |          |         |
| APACHE   | Correlation | 0.008  | -0.172 |          |         |          |         |
| Sig. (2-tailed) | 0.975 | 0.467  |          |         |         |          |         |
| P/F 1    | Correlation | 0.027  | -0.077 |          |         |          |         |
| Sig. (2-tailed) | 0.909 | 0.48   |          |         |         |          |         |
| P/F 3    | Correlation | -0.289  | -0.075 |          |         |          |         |
| Sig. (2-tailed) | 0.277 | 0.774  |          |         |         |          |         |
| P/F 7    | Correlation | -0.361  | 0.383  |          |         |          |         |
| Sig. (2-tailed) | 0.117 | 0.095  |          |         |         |          |         |
| MAP 1    | Correlation | -0.226  | 0.118  |          |         |          |         |
| Sig. (2-tailed) | 0.401 | 0.651  |          |         |         |          |         |
| MAP 3    | Correlation | 0.002  | -0.513 |          |         |          |         |
| Sig. (2-tailed) | -0.996 | 0.129  |          |         |         |          |         |
| MAP 7    | Correlation | 0.019  | 0.170  | 0.000  | -0.211  | 0.342  | -0.342  |
| Sig. (2-tailed) | 0.94  | 0.473  | 1       | 0.417  | 0.334  | 0.334   |

APACHE II, Acute Physiology and Chronic Health Evaluation; MAP, mean arterial pressure; P/F, PaO2/FiO2 (as a respiratory index); SOFA, Sequential Organ Failure Assessment.
experimental data. Although, Engel et al observed that taurine concentration was reduced in neutrophil cells, our results indicated that the taurine concentration in the patients’ blood and blood cells were higher than that of the control group. Neutrophils is the main component of white blood cells in a state of sepsis; therefore, the concentration of taurine in neutrophils is high. In their study, the reduced level of taurine in plasma and blood cells was maintained, and no significant change was observed compared to patients with trauma. Like ours, they did not find any correlation between plasma and intracellular concentrations.\(^9\) Vinton et al\(^9\) showed that the taurine level in plasma, platelets and white blood cells in critically ill patients admitted to the ICU was lower than that in healthy subjects, while the amount of taurine in granulocytes was stable, and no significant change was observed compared to the control group. Vente et al measured taurine level in plasma and other amino acids of 65 patients of whom 27 and 38 patients were septic and had SIRS, respectively.\(^7\) The results showed that the plasma concentration of amino acids, including taurine in septic and SIRS patients was significantly lower than that of the control group. The taurine level reduction in the plasma of septic and stressed patients had no significant difference. However, taurine level in severe sepsis was lower than the mild to moderate level. In the present study, taurine level in the blood and plasma of 6 died patients compared to 14 survived patients was not significantly different. It may be concluded that taurine level in blood or plasma is an inappropriate indicator to predict mortality or survival of septic patients. Taurine concentration in plasma is not higher than other amino acids concentration, but taurine intracellular level is often up to 10 times higher than other amino acids except glutamate.\(^9\) Taurine is approximately 76% and 50% of free amino acids into granulocytes and lymphocytes, respectively. Furthermore, a beta-amino acid transmitter system in lymphocytes maintains the high endogenous taurine level of plasma. Taurine therapy includes potential advantages in reduction of the neutrophils and tissue damage resulted from sepsis. These phenomena can be explained by antioxidant and membrane stabilizer effects of taurine. The important role of taurine in the immune system and anti-inflammatory effects with high doses in neutrophils and lymphocytes have been proposed.\(^10\) The activity of white blood cells and their need to promote the capacity of antioxidants and phagocytosis in sepsis justify the accumulation of plasma taurine in blood cells. This accumulation is probably due to its influx from plasma to white blood cells. Therefore, we cannot definitely claim that the lack of taurine in plasma is a logical reason for administration of taurine supplementation in septic patients since the taurine concentration in blood was higher than that of the control group. Furthermore, the lack of correlation between taurine concentration in plasma and blood supports this idea. In line with other studies, we found no correlation between SOFA score of septic patients and taurine level in plasma and neutrophils. Consequently, taurine levels are not associated with disease severity (APACHE II score). The results are inconsistent with the literature.\(^17,19,28\)

In the present study, no significant correlation between age, sex, and taurine concentration in blood and plasma were found. In agreement with the previous study,\(^8\) we found no correlation between arterial blood pressure and taurine level in blood and plasma. Furthermore, no correlation was found between taurine levels in plasma and blood and vasopressor as well as inotrope administration in septic patients and hemodynamic abnormalities. We evaluated respiratory insufficiency using the Po2/Fio2 index. Taurine levels in blood and plasma did not show any significant correlation with this index.

The results showed a direct and significant correlation between taurine level in plasma and lactate level in blood on the third day. Furthermore, taurine level in blood and plasma was indirectly and significantly correlated with lactate level in blood on the seventh day. Chiarla et al\(^18\) demonstrated a significant correlation between taurine level in plasma and lactate level in blood. Lactate level in blood is a tissue hypoperfusion marker indicating sepsis severity. This level negatively and positively correlates with taurine levels in plasma and blood, respectively.

**Conclusion**

In septic patients, taurine concentration in plasma and blood are lower and higher, respectively comparing with healthy control population. These concentrations are not correlated to each other and also not correlated with the patients’ outcome, the disease severity and organ failure.

**Acknowledgments**

We thank Clinical Research Development Unit, Imam Reza General Hospital for their technical acceptance in manuscript preparation.

**Author Contributions**

**Conceptualization:** Ata Mahmodpoor, Hadi Hamishehkar.

**Data curation:** Niloufar Farzan, Farnaz Naeimzadeh, Parina Asgharian.

**Data collection, patient recruitment:** Kamran shadvar, Ata Mahmodpoor.

**samples Analysis:** Afsaneh Farjami, Hamed Hamishehkar.

**Investigation:** Sarvin Sanaie, Parina Asgharian.

**Methodology:** Ata Mahmodpoor, Hadi Hamishehkar, Sarvin Sanaie.

**Project administration:** Hadi Hamishehkar.

**Writing – original draft:** Niloufar Farzan, Parina Asgharian.

**Writing – review & editing:** Farnaz Naeimzadeh.

**Ethical Issues**

This study is based on the principles outlined in the Declaration of Helsinki, and its ethical code was obtained from the Medical Ethics Committee. The written consent form was obtained from all the patients’ legal representatives.

**Conflict of Interest**

The authors declare no conflict of interest.
Taurine in septic critically ill patients

References

1. Koekkoek WA, van Zanten AR. Antioxidant vitamins and trace elements in critical illness. *Nutr Clin Pract* 2016;31(4):457-74. doi: 10.1177/0884536316635382

2. Parish M, Valiyi F, Hamishehkhar H, Sanaie S, Aghashi Jafarabadi M, Ejl Grolzari S, et al. The effect of omega-3 fatty acids on ARDS: a randomized double-blind study. *Adv Pharm Bull* 2014;4(Suppl 2):553-61. doi: 10.3681/apb.2014.082

3. Zolali E, Asgharitan P, Hamishehkhar H, Khousooltani M, Khodai H, Hamishehkhar H. Effects of gamma oryzanol on factors of oxidative stress and sepsis-induced lung injury in experimental animal model. *Iran J Basic Med Sci* 2015;18(12):1257-63.

4. Mahmoodpoor A, Hamishehkhar H, Sanaie S, Behruzizad N, Iranpour A, Koleini E, et al. Antioxidant reserve of the lungs and ventilator-associated pneumonia: a clinical trial of high dose selenium in critically ill patients. *J Crit Care* 2018;44:357-62. doi: 10.1016/j.jcrc.2017.12.016

5. Huxtable RJ, Sebring LS. Towards a unifying theory for the actions of taurine. *Trends Pharmacol Sci* 1986;7:481-5. doi: 10.1016/0040-8755(86)90043-5

6. Redmond HP, Stapleton PP, Neary P, Boucher-Hayes D. Immunonutrition: the role of taurine. *Nutrition* 1998;14(7-8):599-604. doi: 10.1016/s0899-9007(98)00097-5

7. Fazzino F, Urbina M, Mata S, Lima L. Taurine transport and transporter localization in peripheral blood lymphocytes of controls and major depression patients. *Adv Exp Med Biol* 2006;583:423-6. doi: 10.1007/978-0-387-33504-9_48

8. Vinton NE, Laidlaw SA, Ament ME, Kopple JD. Taurine concentrations in plasma, blood cells, and urine of children undergoing long-term total parenteral nutrition. *Pediatr Res* 1987;21(4):399-403. doi: 10.1203/00006450-198704000-00016

9. Boldreyee AA, Johnson P, Wei Y, Tan Y, Carpenter DO. Carnosine and taurine protect rat cerebellar granular cells from free radical damage. *Neurosci Lett* 1999;263(2-3):169-72. doi: 10.1016/s0304-3940(99)00150-0

10. Learn DB, Fried VA, Thomas EL. Taurine and hypotaurine content of human leukocytes. *J Leukoc Biol* 1990;48(2):174-82.

11. Grimbble RF. The effects of sulfur amino acid intake on immune function in humans. *J Nutr* 2006;136(6 Suppl):1660S-SS. doi: 10.1093/jn/136.6.1660S

12. Askanjazi J, Carpenter YT, Michelsen CB, Elwyn DH, Forst P, Kantonwitz LR, et al. Muscle and plasma amino acids following injury. Influence of intercurrent infection. *Ann Surg* 1980;192(1):78-85. doi: 10.1097/00000658-198007000-00014

13. Chiara C, Giovannini I, Siegel JH, Boldrini G, Castagneto M. The relationship between plasma taurine and other amino acid levels in human sepsis. *Surgery* 1990;100(9):2222-7. doi: 10.1093/jn/130.9.2222

14. Waterfield CJ, Turton JA, Scales MD, Timbrell JA. Taurine, a possible urinary marker of liver damage: a study of taurine excretion in carbon tetrachloride-treated rats. *Arch Toxicol* 1991;65(7):548-55. doi: 10.1007/bf01973717

15. Freund H, Atamian S, Holroyde J, Fischer JE. Plasma amino acids as predictors of the severity and outcome of sepsis. *Ann Surg* 1979;180(5):571-6. doi: 10.1097/00000658-197911000-00003

16. Cloves GH Jr, Randall HT, Cha CJ. Amino acid and energy metabolism in septic and traumatized patients. *JPEN J Parenter Enteral Nutr* 1980;4(2):195-205. doi: 10.1016/0148-6077(80)000225

17. Vente JP, von Meyenfeldt MF, van Eijk HM, van Berlo CL, Gouma DJ, van der Linden CJ, et al. Plasma-amino acid profiles in sepsis and stress. *Ann Surg* 1989;209(1):57-62. doi: 10.1097/00000658-198901000-00009

18. Chiara C, Giovannini I, Siegel JH, Boldrini G, Castagneto M. Taurine and pulmonary hemodynamics in sepsis. *Amino Acids* 2000;18(4):389-97. doi: 10.1007/pk00021419

19. Engel JM, Mühlhug J, Weiss S, Kärcher B, Lühr T, Menges T, et al. Relationship of taurine and other amino acids in plasma and in neutrophils of septic trauma patients. *Amino Acids* 2006;30(1):87-94. doi: 10.1007/s00726-005-0238-1

20. Vermeulen MA, van Stijin MF, Visser M, Lennons SM, Houdijk AP, van Leeuwen PA, et al. Taurine concentrations decrease in critically ill patients with shock given enteral nutrition. *JPEN J Parenter Enteral Nutr* 2016;40(2):264-72. doi: 10.1177/014860711567199

21. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Intensive Care Med* 2003;29(4):530-8. doi: 10.1007/s00134-003-1662-x

22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med* 1983;13(10):818-29.

23. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. *Crit Care Med* 1998;26(11):1793-800. doi: 10.1097/00003146-199811000-00016

24. Kass DO, Choli-Papadopoulou T, Wittmann-Liebold B. *Protein Structure Analysis: Preparation, Characterization, and Microsequencing*. Switzerland: Springer Science & Business Media; 1997.

25. Ali M, Erikoglu M, Kaynak A, Esen HH, Kurbans. The effects of selenium and vitamin E on lung tissue in rats with sepsis. *Clin Invest Med* 2012;35(2):E48-54. doi: 10.2501/cim.1352.1203

26. Levy MM, Dellinger RP, Townsmd SR, Linde-Zwirble WT, Marshall JC, Bion J, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. *Intensive Care Med* 2010;36(2):222-31. doi: 10.1007/s00134-009-1738-3

27. Rozen R, Scrivcr CR. Renal transport of taurine adapts to perturbed taurine homeostasis. *Proc Natl Acad Sci USA* 1982;79(6):2101-5. doi: 10.1073/pnas.79.6.2101

28. Pauw JD, Davis AT. Taurine concentrations in serum of critically injured patients and age- and sex-matched healthy control subjects. *Am J Clin Nutr* 1990;52(4):657-60. doi: 10.1093/ajcn/52.4.657

29. Vinton NE, Laidlaw SA, Ament ME, Kopple JD. Taurine concentrations in plasma and blood cells of patients undergoing long-term parenteral nutrition. *Am J Clin Nutr* 1990;52(4):657-60. doi: 10.1093/ajcn/52.4.657

30. Vinton NE, Laidlaw SA, Ament ME, Kopple JD. Taurine concentrations in plasma and blood cells of patients undergoing long-term parenteral nutrition. *Am J Clin Nutr* 1986;44(3):398-404. doi: 10.1093/ajcn/44.3.398

31. Jacobsen JG, Smith LH. Biochemistry and physiology of taurine and taurine derivatives. *Physiol Rev* 1968;48(2):424-511. doi: 10.1152/physrev.1968.48.2.424

32. Banks MA, Porter DW, Martin WG, Castronova V. Taurine protects against oxidant injury to rat alveolar pneumocytes. *Adv Exp Med Biol* 1992;315:341-54. doi: 10.1007/978-1-4615-3436-5_40